1401-P: Psychotropic Drug Use in Children and Adolescents with Type 1 Diabetes
Psychiatric disorders in children and adolescents with type 1 diabetes (T1D) have caught increasing attention. While psychotropic drugs offer great value in managing psychiatric symptoms, their adverse effects engender considerable controversy regarding their use in pediatric patients, let alone in...
Gespeichert in:
| Veröffentlicht in: | Diabetes (New York, N.Y.) N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_1 |
| container_start_page | 1 |
| container_title | Diabetes (New York, N.Y.) |
| container_volume | 72 |
| creator | LIU, SHENGXIN LAGERBERG, TYRA LUDVIGSSON, JONAS F. TAYLOR, MARK DONOFRIO, BRIAN LICHTENSTEIN, PAUL GUDBJÖRNSDOTTIR, SOFFIA BUTWICKA, AGNIESZKA |
| description | Psychiatric disorders in children and adolescents with type 1 diabetes (T1D) have caught increasing attention. While psychotropic drugs offer great value in managing psychiatric symptoms, their adverse effects engender considerable controversy regarding their use in pediatric patients, let alone in those with T1D. Despite the topic’s high visibility, little evidence exists on the patterns of psychotropic drug use in pediatric T1D patients. We thus conducted this cohort study of 3,720,381 children and adolescents (13,191 [0.36%] had T1D) using several Swedish national registers. We examined the trends and patterns (prescription source and treatment duration) of psychotropic drug use and estimated the risk of initiating psychotropic drugs after T1D onset. We found that psychotropic drug use increased significantly in children and adolescents with T1D from 2006 to 2019 (Figure 1), with ADHD medications, SSRI, hypnotics and anxiolytics among the most used ones. The primary prescription source was psychiatric care, and treatment durations were mostly |
| doi_str_mv | 10.2337/db23-1401-P |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2849361146</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2849361146</sourcerecordid><originalsourceid>FETCH-LOGICAL-c646-78cf97df0c505f43f6150ed72069dcb53a602b9194766d403925b9ebf09c237c3</originalsourceid><addsrcrecordid>eNotkEtLw0AYRQdRsFZX_oEBlzL6zSMzHXcl9QVFu6jgbkjmYVNiEmcSJP_elshd3M3hXjgIXVO4Y5yre1cyTqgASjYnaEY114Qz9XmKZgCUEaq0OkcXKe0BQB4yQ28T_YA3abS7to9tV1m8isMX_kgeVw3Od1Xtom9w0Ti8dG3tk_VNn_Bv1e_wduw8pnhVFaXvfbpEZ6Gok7_67znaPj1u8xeyfn9-zZdrYqWQRC1s0MoFsBlkQfAgaQbeKQZSO1tmvJDASk21UFI6AVyzrNS-DKAt48ryObqZZrvY_gw-9WbfDrE5PBq2EJpLSoU8ULcTZWObUvTBdLH6LuJoKJijL3P0ZY4GzIb_ARtsWqk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2849361146</pqid></control><display><type>article</type><title>1401-P: Psychotropic Drug Use in Children and Adolescents with Type 1 Diabetes</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>LIU, SHENGXIN ; LAGERBERG, TYRA ; LUDVIGSSON, JONAS F. ; TAYLOR, MARK ; DONOFRIO, BRIAN ; LICHTENSTEIN, PAUL ; GUDBJÖRNSDOTTIR, SOFFIA ; BUTWICKA, AGNIESZKA</creator><creatorcontrib>LIU, SHENGXIN ; LAGERBERG, TYRA ; LUDVIGSSON, JONAS F. ; TAYLOR, MARK ; DONOFRIO, BRIAN ; LICHTENSTEIN, PAUL ; GUDBJÖRNSDOTTIR, SOFFIA ; BUTWICKA, AGNIESZKA</creatorcontrib><description>Psychiatric disorders in children and adolescents with type 1 diabetes (T1D) have caught increasing attention. While psychotropic drugs offer great value in managing psychiatric symptoms, their adverse effects engender considerable controversy regarding their use in pediatric patients, let alone in those with T1D. Despite the topic’s high visibility, little evidence exists on the patterns of psychotropic drug use in pediatric T1D patients. We thus conducted this cohort study of 3,720,381 children and adolescents (13,191 [0.36%] had T1D) using several Swedish national registers. We examined the trends and patterns (prescription source and treatment duration) of psychotropic drug use and estimated the risk of initiating psychotropic drugs after T1D onset. We found that psychotropic drug use increased significantly in children and adolescents with T1D from 2006 to 2019 (Figure 1), with ADHD medications, SSRI, hypnotics and anxiolytics among the most used ones. The primary prescription source was psychiatric care, and treatment durations were mostly <12 months (except for ADHD medications). Children and adolescents with newly-onset T1D had a higher risk of initiating any psychotropic drug (hazard ratio 1.29, 95%CI 1.20-1.38) than their peers without T1D. Our findings highlight the need for risk/benefit studies of psychotropic drugs among young users with T1D to inform future research and guideline development.</description><identifier>ISSN: 0012-1797</identifier><identifier>EISSN: 1939-327X</identifier><identifier>DOI: 10.2337/db23-1401-P</identifier><language>eng</language><publisher>New York: American Diabetes Association</publisher><subject>Adolescents ; Anxiolytics ; Attention deficit hyperactivity disorder ; Children ; Diabetes ; Diabetes mellitus (insulin dependent) ; Drug use ; Hypnotics ; Mental disorders ; Patients ; Pediatrics ; Psychotropic drugs ; Serotonin uptake inhibitors ; Teenagers</subject><ispartof>Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1</ispartof><rights>Copyright American Diabetes Association Jun 2023</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids></links><search><creatorcontrib>LIU, SHENGXIN</creatorcontrib><creatorcontrib>LAGERBERG, TYRA</creatorcontrib><creatorcontrib>LUDVIGSSON, JONAS F.</creatorcontrib><creatorcontrib>TAYLOR, MARK</creatorcontrib><creatorcontrib>DONOFRIO, BRIAN</creatorcontrib><creatorcontrib>LICHTENSTEIN, PAUL</creatorcontrib><creatorcontrib>GUDBJÖRNSDOTTIR, SOFFIA</creatorcontrib><creatorcontrib>BUTWICKA, AGNIESZKA</creatorcontrib><title>1401-P: Psychotropic Drug Use in Children and Adolescents with Type 1 Diabetes</title><title>Diabetes (New York, N.Y.)</title><description>Psychiatric disorders in children and adolescents with type 1 diabetes (T1D) have caught increasing attention. While psychotropic drugs offer great value in managing psychiatric symptoms, their adverse effects engender considerable controversy regarding their use in pediatric patients, let alone in those with T1D. Despite the topic’s high visibility, little evidence exists on the patterns of psychotropic drug use in pediatric T1D patients. We thus conducted this cohort study of 3,720,381 children and adolescents (13,191 [0.36%] had T1D) using several Swedish national registers. We examined the trends and patterns (prescription source and treatment duration) of psychotropic drug use and estimated the risk of initiating psychotropic drugs after T1D onset. We found that psychotropic drug use increased significantly in children and adolescents with T1D from 2006 to 2019 (Figure 1), with ADHD medications, SSRI, hypnotics and anxiolytics among the most used ones. The primary prescription source was psychiatric care, and treatment durations were mostly <12 months (except for ADHD medications). Children and adolescents with newly-onset T1D had a higher risk of initiating any psychotropic drug (hazard ratio 1.29, 95%CI 1.20-1.38) than their peers without T1D. Our findings highlight the need for risk/benefit studies of psychotropic drugs among young users with T1D to inform future research and guideline development.</description><subject>Adolescents</subject><subject>Anxiolytics</subject><subject>Attention deficit hyperactivity disorder</subject><subject>Children</subject><subject>Diabetes</subject><subject>Diabetes mellitus (insulin dependent)</subject><subject>Drug use</subject><subject>Hypnotics</subject><subject>Mental disorders</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Psychotropic drugs</subject><subject>Serotonin uptake inhibitors</subject><subject>Teenagers</subject><issn>0012-1797</issn><issn>1939-327X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNotkEtLw0AYRQdRsFZX_oEBlzL6zSMzHXcl9QVFu6jgbkjmYVNiEmcSJP_elshd3M3hXjgIXVO4Y5yre1cyTqgASjYnaEY114Qz9XmKZgCUEaq0OkcXKe0BQB4yQ28T_YA3abS7to9tV1m8isMX_kgeVw3Od1Xtom9w0Ti8dG3tk_VNn_Bv1e_wduw8pnhVFaXvfbpEZ6Gok7_67znaPj1u8xeyfn9-zZdrYqWQRC1s0MoFsBlkQfAgaQbeKQZSO1tmvJDASk21UFI6AVyzrNS-DKAt48ryObqZZrvY_gw-9WbfDrE5PBq2EJpLSoU8ULcTZWObUvTBdLH6LuJoKJijL3P0ZY4GzIb_ARtsWqk</recordid><startdate>20230620</startdate><enddate>20230620</enddate><creator>LIU, SHENGXIN</creator><creator>LAGERBERG, TYRA</creator><creator>LUDVIGSSON, JONAS F.</creator><creator>TAYLOR, MARK</creator><creator>DONOFRIO, BRIAN</creator><creator>LICHTENSTEIN, PAUL</creator><creator>GUDBJÖRNSDOTTIR, SOFFIA</creator><creator>BUTWICKA, AGNIESZKA</creator><general>American Diabetes Association</general><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20230620</creationdate><title>1401-P: Psychotropic Drug Use in Children and Adolescents with Type 1 Diabetes</title><author>LIU, SHENGXIN ; LAGERBERG, TYRA ; LUDVIGSSON, JONAS F. ; TAYLOR, MARK ; DONOFRIO, BRIAN ; LICHTENSTEIN, PAUL ; GUDBJÖRNSDOTTIR, SOFFIA ; BUTWICKA, AGNIESZKA</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c646-78cf97df0c505f43f6150ed72069dcb53a602b9194766d403925b9ebf09c237c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Adolescents</topic><topic>Anxiolytics</topic><topic>Attention deficit hyperactivity disorder</topic><topic>Children</topic><topic>Diabetes</topic><topic>Diabetes mellitus (insulin dependent)</topic><topic>Drug use</topic><topic>Hypnotics</topic><topic>Mental disorders</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Psychotropic drugs</topic><topic>Serotonin uptake inhibitors</topic><topic>Teenagers</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>LIU, SHENGXIN</creatorcontrib><creatorcontrib>LAGERBERG, TYRA</creatorcontrib><creatorcontrib>LUDVIGSSON, JONAS F.</creatorcontrib><creatorcontrib>TAYLOR, MARK</creatorcontrib><creatorcontrib>DONOFRIO, BRIAN</creatorcontrib><creatorcontrib>LICHTENSTEIN, PAUL</creatorcontrib><creatorcontrib>GUDBJÖRNSDOTTIR, SOFFIA</creatorcontrib><creatorcontrib>BUTWICKA, AGNIESZKA</creatorcontrib><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><jtitle>Diabetes (New York, N.Y.)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>LIU, SHENGXIN</au><au>LAGERBERG, TYRA</au><au>LUDVIGSSON, JONAS F.</au><au>TAYLOR, MARK</au><au>DONOFRIO, BRIAN</au><au>LICHTENSTEIN, PAUL</au><au>GUDBJÖRNSDOTTIR, SOFFIA</au><au>BUTWICKA, AGNIESZKA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1401-P: Psychotropic Drug Use in Children and Adolescents with Type 1 Diabetes</atitle><jtitle>Diabetes (New York, N.Y.)</jtitle><date>2023-06-20</date><risdate>2023</risdate><volume>72</volume><issue>Supplement_1</issue><spage>1</spage><pages>1-</pages><issn>0012-1797</issn><eissn>1939-327X</eissn><abstract>Psychiatric disorders in children and adolescents with type 1 diabetes (T1D) have caught increasing attention. While psychotropic drugs offer great value in managing psychiatric symptoms, their adverse effects engender considerable controversy regarding their use in pediatric patients, let alone in those with T1D. Despite the topic’s high visibility, little evidence exists on the patterns of psychotropic drug use in pediatric T1D patients. We thus conducted this cohort study of 3,720,381 children and adolescents (13,191 [0.36%] had T1D) using several Swedish national registers. We examined the trends and patterns (prescription source and treatment duration) of psychotropic drug use and estimated the risk of initiating psychotropic drugs after T1D onset. We found that psychotropic drug use increased significantly in children and adolescents with T1D from 2006 to 2019 (Figure 1), with ADHD medications, SSRI, hypnotics and anxiolytics among the most used ones. The primary prescription source was psychiatric care, and treatment durations were mostly <12 months (except for ADHD medications). Children and adolescents with newly-onset T1D had a higher risk of initiating any psychotropic drug (hazard ratio 1.29, 95%CI 1.20-1.38) than their peers without T1D. Our findings highlight the need for risk/benefit studies of psychotropic drugs among young users with T1D to inform future research and guideline development.</abstract><cop>New York</cop><pub>American Diabetes Association</pub><doi>10.2337/db23-1401-P</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0012-1797 |
| ispartof | Diabetes (New York, N.Y.), 2023-06, Vol.72 (Supplement_1), p.1 |
| issn | 0012-1797 1939-327X |
| language | eng |
| recordid | cdi_proquest_journals_2849361146 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adolescents Anxiolytics Attention deficit hyperactivity disorder Children Diabetes Diabetes mellitus (insulin dependent) Drug use Hypnotics Mental disorders Patients Pediatrics Psychotropic drugs Serotonin uptake inhibitors Teenagers |
| title | 1401-P: Psychotropic Drug Use in Children and Adolescents with Type 1 Diabetes |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-12T22%3A33%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1401-P:%20Psychotropic%20Drug%20Use%20in%20Children%20and%20Adolescents%20with%20Type%201%20Diabetes&rft.jtitle=Diabetes%20(New%20York,%20N.Y.)&rft.au=LIU,%20SHENGXIN&rft.date=2023-06-20&rft.volume=72&rft.issue=Supplement_1&rft.spage=1&rft.pages=1-&rft.issn=0012-1797&rft.eissn=1939-327X&rft_id=info:doi/10.2337/db23-1401-P&rft_dat=%3Cproquest_cross%3E2849361146%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2849361146&rft_id=info:pmid/&rfr_iscdi=true |